Glomerulonephritis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Glomerulonephritis – Pipeline Review, H2 2017’, provides an overview of the Glomerulonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis

The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects

The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Glomerulonephritis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achillion Pharmaceuticals Inc

Anthera Pharmaceuticals Inc

Biogen Inc

Bristol-Myers Squibb Company

Cellmid Ltd

ChemoCentryx Inc

Complexa Inc

Dimerix Bioscience Pty Ltd

GlaxoSmithKline Plc

Merck KGaA

Omeros Corp

Pfizer Inc

Pharmalink AB

Ra Pharmaceuticals Inc

Retrophin Inc

Rigel Pharmaceuticals Inc

Shire Plc

Visterra Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Glomerulonephritis - Overview 6

Glomerulonephritis - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Glomerulonephritis - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 18

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Glomerulonephritis - Companies Involved in Therapeutics Development 25

Achillion Pharmaceuticals Inc 25

Anthera Pharmaceuticals Inc 25

Biogen Inc 26

Bristol-Myers Squibb Company 26

Cellmid Ltd 27

ChemoCentryx Inc 27

Complexa Inc 28

Dimerix Bioscience Pty Ltd 28

GlaxoSmithKline Plc 28

Merck KGaA 29

Omeros Corp 30

Pfizer Inc 30

Pharmalink AB 31

Ra Pharmaceuticals Inc 31

Retrophin Inc 32

Rigel Pharmaceuticals Inc 32

Shire Plc 33

Visterra Inc 33

Glomerulonephritis - Drug Profiles 34

(irbesartan + propagermanium) - Drug Profile 34

abatacept - Drug Profile 38

ACH-4471 - Drug Profile 47

ACH-5228 - Drug Profile 50

AMY-101 - Drug Profile 51

atacicept - Drug Profile 53

avacopan - Drug Profile 56

AVX-002 - Drug Profile 63

BaxB-01 - Drug Profile 64

BaxG-03 - Drug Profile 66

belimumab - Drug Profile 68

blisibimod - Drug Profile 75

budesonide - Drug Profile 83

CAB-102 - Drug Profile 86

CCX-140 - Drug Profile 88

CXA-10 - Drug Profile 92

ERG-240 - Drug Profile 94

fostamatinib disodium - Drug Profile 95

losmapimod - Drug Profile 101

Monoclonal Antibodies to Inhibit ITGAM for Cardiovascular, Immunology and Kidney Diseases - Drug Profile 104

OMS-721 - Drug Profile 105

PBF-677 - Drug Profile 115

PF-06730512 - Drug Profile 116

PF-1355 - Drug Profile 117

Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile 118

rituximab - Drug Profile 119

SHP-627 - Drug Profile 126

Small Molecule to Inhibit Factor D for C3 glomerulopathy and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 128

sparsentan - Drug Profile 129

Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile 133

TM-5484 - Drug Profile 134

Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 135

VAR-200 - Drug Profile 136

VIS-649 - Drug Profile 137

Glomerulonephritis - Dormant Projects 138

Glomerulonephritis - Discontinued Products 140

Glomerulonephritis - Product Development Milestones 141

Featured News & Press Releases 141

Appendix 153

Methodology 153

Coverage 153

Secondary Research 153

Primary Research 153

Expert Panel Validation 153

Contact Us 153

Disclaimer 154

List of Tables

List of Tables

Number of Products under Development for Glomerulonephritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Glomerulonephritis – Pipeline by Achillion Pharmaceuticals Inc, H2 2017

Glomerulonephritis – Pipeline by Anthera Pharmaceuticals Inc, H2 2017

Glomerulonephritis – Pipeline by Biogen Inc, H2 2017

Glomerulonephritis – Pipeline by Bristol-Myers Squibb Company, H2 2017

Glomerulonephritis – Pipeline by Cellmid Ltd, H2 2017

Glomerulonephritis – Pipeline by ChemoCentryx Inc, H2 2017

Glomerulonephritis – Pipeline by Complexa Inc, H2 2017

Glomerulonephritis – Pipeline by Dimerix Bioscience Pty Ltd, H2 2017

Glomerulonephritis – Pipeline by GlaxoSmithKline Plc, H2 2017

Glomerulonephritis – Pipeline by Merck KGaA, H2 2017

Glomerulonephritis – Pipeline by Omeros Corp, H2 2017

Glomerulonephritis – Pipeline by Pfizer Inc, H2 2017

Glomerulonephritis – Pipeline by Pharmalink AB, H2 2017

Glomerulonephritis – Pipeline by Ra Pharmaceuticals Inc, H2 2017

Glomerulonephritis – Pipeline by Retrophin Inc, H2 2017

Glomerulonephritis – Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Glomerulonephritis – Pipeline by Shire Plc, H2 2017

Glomerulonephritis – Pipeline by Visterra Inc, H2 2017

Glomerulonephritis – Dormant Projects, H2 2017

Glomerulonephritis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Glomerulonephritis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Glomerulonephritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports